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Abstract 
Eosinophilic diseases of the gastrointestinal tract, including eosinophilic esophagitis (EoE) and eosinophilic gastroen-
teritis (EGE), are rare chronic pathologies of the digestive system, with an immuno-mediated pathogenesis. Recent 
data suggest that, together with the “classic” IgE-response to allergens, also a delayed hypersensitivity mechanism 
could be involved in the development of eosinophilic disorders. EoE and EGE were studied only in the latest decades 
and as a consequence accurate data are not yet available, concerning not only pathogenesis, but also epidemiology, 
treatment and outcomes. The diagnosis of EoE is centered on endoscopic findings but the certainty is obtained by 
histological examination from biopsy samples, that has a sensitivity of 100% when based on five samples. The cur-
rently available treatments include topical corticosteroids, specific diets and endoscopic treatment. Concerning EGE, 
three subtypes (mucosal, muscular, and serosal) were identified. The diagnosis is based, as for EoE, on endoscopic 
and histological assessment, and the treatment includes pharmacological and dietetic approaches. Further studies 
are warranted in order to better define the etiology and pathogenesis of eosinophilic diseases of the gastrointestinal 
tract, and thus to develop more appropriate and specific therapies.
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Background
Primitive eosinophilic esophagitis (EoE) and eosino-
philic gastroenteritis are part of a group of diseases first 
described in 1937 by Kaijser and called EGIDs (eosino-
philic gastrointestinal diseases) [1]. These clinical entities 
are characterized by selective infiltration of gastrointes-
tinal tract by eosinophils, in absence of other causes of 
known eosinophilia.
Interest in EGIDs dates back to the latest decades and, 
also due to the rarity of these disorders, the data about 
epidemiology, pathogenesis, therapy and outcomes thus 
far available are partial. There is an urgent need to bet-
ter characterize EGIDs, to understand the etiology and 
to define a more precise therapeutic approach. In fact, 
current treatments are yet controversial and there is no 
consensus on how long the diet and/or steroid therapy 
should be maintained.
Eosinophilic esophagitis
EoE is a chronic inflammatory disease of the esophagus 
with an immuno-allergic pathogenesis, characterized by 
eosinophilic infiltration (≥15 Eo/high power field [HPF]) 
and secondary fibrosis [1]. EoE was once considered a 
rare clinical entity and in fact it was relatively unknown 
until the ‘90s, while now it is of increasing interest.
In United States and Europe epidemiological stud-
ies found a prevalence of EoE of 50 patients per 100.000 
inhabitants [2].
EoE can affect any age, from infancy to old age, but 
diagnosis is more frequent in third/fourth decades [3]. 
Male subjects are more frequently affected than females, 
with a rate of 3:1 [2, 3]. The reason for this gender dif-
ference is not yet explained, but a single nucleotide 
polymorphism (SNP) in the gene for thymic stromal 
lymphopoietin (TSLP), was identified on chromosome 
Xp22.3 and also on chromosome Yp11.3. These find-
ings can be a possible explanation for the prevalence of 
EoE in males [4]. Caucasian ethnicity is more commonly 
interested in EoE, with a reported predominance of 90% 
in some case studies. However, the disease can affect also 
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African American, Asian, Native American and Hispanic 
populations [5].
Pathogenesis
EoE pathogenesis is complex with many factors involved, 
particularly genetic and environmental, and the pre-
cise mechanism is still unknown. Environmental factors 
seems to play a significant role in development of EoE: in 
fact, though the heritability rate is about 70%, concord-
ance between monozygotic twins is only 30%, suggesting 
a powerful role for environmental factors (81.0%) [6]. An 
important epidemiological study, conducted in Cincin-
nati (US) evaluated 6108 individuals from 1366 families 
of patients with EoE: the recurrence risk ratio was found 
to be increased 10- to 64-fold compared with the general 
population, with an incidence of EoE in relatives from 1.8 
to 2.4%, depending on relationship and sex [6].
In literature, an association between EoE and some 
hereditary collagen alterations, such as Marfan and 
Enhlers-Danlos syndromes, was reported [7]. More 
recently another associated disease was reported: three 
patients with EoE suffered from hypertrophic cardiomyo-
pathy, leading the Authors to suggest a possible genetic 
alteration underling both diseases [8].
Several genetic alterations have been identified in 
patients with EoE. The most common involved gene 
is the one for eotaxin-3, a chemokine active on eosino-
phils, that plays a fundamental role in EoE. In fact, it is 
expressed in esophageal mucosa 53 times more than in 
healthy subjects. The alteration is represented by SNP in 
the 3′ untranslated region of eotaxin-3 gene [5, 9].
Another important mutation concerns the gene for 
TSLP, and its risk alleles, such as rs3806932, present on 
chromosome 5q22. TLSP is a cytokine produced by epi-
thelial cells, whose action consists of inducing a Th2 cell-
mediated response in dendritic cells [10–12]. Also a SNP 
for TLSP-receptor seems to be involved and its presence 
on chromosome Y could be a possible cause of male 
prevalence for EoE [11].
A recent study suggested a possible mechanism under-
ling the role of TLSP for development of EoE. According 
to these results specific food antigens (hen’s egg ovalbu-
min) can trigger TSLP secretion by differentiated epithe-
lial cells in esophagus [13].
While eotaxin-3 and TLSP are responsible for epithe-
lial dysregulation, also the barrier function is altered in 
EoE. In this case other two proteins are involved: filag-
grin and desmoglein-1.
A SNP of the gene for filaggrin (2282del4) was ana-
lyzed in a cohort of 365 patients with EoE compared to 
165 healthy subjects, showing a significantly associa-
tion with the disease (OR = 5.0) [11]. The hyperplasia 
of esophageal epithelial cells observed in patients with 
EoE is secondary to decreased expression of genes that 
regulate epidermal differentiation. One of these lack-
ing proteins is desmoglein 1 (DSG1), whose action is 
important to maintain an effective barrier in the esoph-
agus [14]. Moreover, downregulation of DSG1 pro-
motes upregulation of periostin, an extracellular matrix 
protein that is involved in fibrosis of the esophagus tis-
sue [15].
The eosinophils’ role is unquestionable, due to the 
production of potent pro-inflammatory mediators, such 
as cytokines, GM-CSF, TGF-β and TNF-α, Th2 lym-
phocytes and their cytokines (IL-5, IL-4, IL-13) that are 
main actors in coordinating adaptive immunity in the 
pathogenesis of EoE. IL-5 is the most important media-
tor for eosinophilic activation and recruitment. Its action 
is confirmed by a study demonstrating its overexpres-
sion in esophageal biopsies from pediatric patients with 
EoE [16]. IL-13 is produced primarily by Th2 cells and its 
activation leads to an increased generation of eotaxin-3. 
High concentrations of IL-13 were detected in esopha-
geal biopsies [17]. IL-4 stimulates, together with IL-13, 
the production of eotaxin-3 [12].
Recently a genome-wide genetic association of EoE was 
identified at 2p23 spanning, the calpain 14 (CAPN14) 
gene. CAPN14 is a gene induced by IL-13 that encodes 
for calpain 14, a cysteine-protease, which is overex-
pressed in esophageal biopsies of patient with EoE [12, 
18]. The role of calpain 14 is not clearly defined, but its 
overexpression results also in loss of desmoglein 1 [18].
IL-13 is responsible to increase the expression of other 
genes involved in EoE pathogenesis, such as BANCR 
(BRAF-activated non-coding RNA) and NTRK1 (Neuro-
tropic Tyrosine Kinase Receptor type 1). RNA sequenc-
ing in esophageal biopsies identified an overexpression 
of lcnRNA BANCR, that is responsible for local hypere-
osinophilia. BANCR is also related to the increase of per-
iostin production [19]. NTRK1 is an early transcription 
target of IL-13 and its expression is higher in esopha-
geal tissue of patients with EoE than in healthy subjects. 
Its increased concentration determines an augmented 
response to its ligand NGF (Neurotropic Tyrosine 
Kinase) that has a primary role in hyperplasia [20]. IL-13 
is also responsible of inducing production of chemokines 
CCL11, CCL24 AND CCL26 from eotaxins [5]. Other 
genetic variants in the cluster of IL-5 and IL-13 regions 
have been identified, but their role is not clearly defined 
[12]. New actors of EoE pathogenesis were recently iden-
tified: mast cells and invariant natural killer T (iNKT).
Mast cells seem to contribute to EoE releasing prosta-
glandin D2 that is able to recruit eosinophils in esopha-
gus [21]. In fact, in animal models of EoE, mast cells are 
increased in number after allergen stimulation, propor-
tionally with time and dose of the stimulus [22].
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iNKT are a subpopulation of T cells, whose concen-
tration in esophageal biopsies of patients with EoE is 
increased compared to healthy subjects. These cells are 
able to recognize the glycolipid antigen and this may 
explain their role in development of EoE: iNKT cell-
deficient CD1d-null mice were protected from food 
allergen-induced EoE, while in the same animals iNKT 
activation is sufficient to induce EoE. In fact, their acti-
vation induces the release of inflammatory cytokines, 
including IL-4, IL-5 and IL-13 [23]. Moreover, a recent 
study suggests that sphingolipids of milk may stimulate 
iNKT cells to produce these cytokines [24].
Another mediator released by eosinophils and implicated 
in EoE pathogenesis is TGF-β1. It mediates the epithelial 
cell proliferation and extracellular remodeling, through the 
upregulation of genes involved in fibrosis, i.e. matrix metal-
loproteinase 2 [12]. Also leukotriene C4 may contribute to 
worsen fibrosis through its metabolites LTD4 and LTE, that 
are able to stimulate smooth cells contraction [5].
The pathogenetic role of atopy was confirmed by exper-
imental and epidemiological studies. EoE is associated 
with a condition of atopy in 75% of patients [5]. Sensiti-
zation regards inhalant and/or food allergens (in adults 
86–93% towards inhalants and 50–82% towards food 
allergens). Sensitization is associated with allergic clinical 
presentations in 68% of adult patients: the most frequent 
symptoms are respiratory (allergic rhinitis 60% approxi-
mately, allergic asthma 39%) [25, 26]. In pediatric patients 
a family history of atopy was present in 73.5% [26]. The 
important effect of food allergy in patients affected by 
EoE is demonstrated indirectly by the improvement of 
symptoms after elimination of allergenic food from diet, 
as we will discuss below. In addition, development of 
EoE was described as a complication of oral tolerance 
induction for food allergens. Ridolo et  al. reported how 
EoE occurred in a 10  year-old child after acquiring tol-
erance for egg with an oral protocol of induction. The 
patient presented dyspepsia and dysphagia 5  months 
after egg reintroduction in diet, with an endoscopic and 
histological demonstration of EoE. Symptoms disap-
peared persistently after elimination of egg from the diet 
[27]. Other cases were described after administration of 
oral specific immunotherapy for milk, egg or peanuts 
[28, 29]. Notably, only a small part of EoE patients with 
food IgE- sensitization presents with anaphylaxis. The 
protection mechanism underlying this aspect is not yet 
well defined, but a recent study highlighted the conceiv-
able role of IgG4 in the development of EoE. In fact, an 
increase in production of IgG4 can be detected in lam-
ina propria of esophagus in biopsies of patients with EoE 
[30]. This hypothesis was formulated after finding that 
omalizumab did not reduce nor symptoms of EoE neither 
tissue eosinophilia compared to placebo in a prospective 
trial. Moreover the Authors observed granular deposits 
of IgG4, plasma cells containing IgG4 and serum lev-
els of IgG4 reactive to specific foods and suggested that 
EoE could be an IgG4-associated pathology [30]. Further 
studies are warranted to confirm these findings.
Regarding the role of inhalant allergens in development 
of EoE, the data in favor of their involvement are certain. 
In a study of Yamazaki et al. mononuclear cells from 25 
patients with EoE were incubated with inhalant allergens 
(dust mites, Aspergillus fumigatus, Alternaria alternata, 
and ragweed pollen): significantly higher levels of IL-5 
and IL-13 were detected in response to the allergens, 
compared than healthy controls, even in the absence 
of an evident IgE-mediated sensitization [31]. Another 
study on animal models demonstrated that intranasal 
exposure to inhalant allergen (A. fumigatus) in sensi-
tized mice induced esophagus eosinophilia, eosinophilic 
degranulation and epithelial hyperplasia [32].
Furthermore, a study performed in patients with 
seasonal respiratory allergy established a correlation 
between esophageal eosinophilic infiltration and sea-
sonal symptoms [33]. In fact a seasonal distribution of 
new diagnoses of EoE was demonstrated: a 1-year study 
highlighted that in 41 adults patients, a new EoE diagno-
sis was more frequent in spring months (44%, 18 of 41 
patients) [10], while a 6-years-long retrospective analysis 
of a pediatric population confirmed that new diagnosis 
were significantly less frequent in winter than in other 
seasons [11]. A retrospective Australian study reported 
a higher recurrence of esophageal food bolus during the 
pollen season in patients with EoE [12].
Moreover patients with EoE presents an high preva-
lence of sensitizations to pan-allergens, responsible for 
cross-reactivity among inhalant and food allergens. In 
particularly, sensitization to PR-10, the birch allergen Bet 
v 1, seems to be very frequent: in a study of Van Rhijn 
39% of patients presents sensitization to this molecule 
[34]. In a recent study the association between bolus as 
first symptom of EoE, more severe eosinophilic infiltra-
tion and sensitization to PR-10 has been established [35].
Of note, there are differences in the sensitization pat-
terns among children and adult population affected by 
EoE, with a progressive increase in inhalant allergy with 
age and a parallel diminution in food sensitization. These 
differences, although not specific for EoE, are correlated 
with patient age and have important therapeutic implica-
tions, suggesting a predominant role of food allergens in 
children.
Clinical presentation
As mentioned above, EoE can affect any age, but clini-
cal presentation differs between children and adult 
patients [26]. In adults the most common symptoms are 
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dysphagia, food bolus, thoracic and epigastric pain, the 
onset being similar to a PPI (Pomp Proton Inhibitors)—
not responding GERD [26]. In pediatric patients the most 
common manifestations are food refusal and growth 
retardation in infants, and vomit, nausea and abdomi-
nal pain in older children [4]. It is important to ascertain 
also the presence of coping mechanism that patients can 
apply during swallow in order to overcome symptoms 
[36].
Endoscopic findings
The possible macroscopic findings during gastroscopy 
are: mucosa edema, white exudates, longitudinal grooves, 
concentric rings (“trachealization” of the esophagus), and 
stenosis. In about 20% of cases esophagus may, however, 
appear macroscopically normal. A meta-analysis includ-
ing 4678 patients with EoE and 2742 controls, estimated 
the following frequency of the endoscopic features: tra-
chealization in 44%, linear grooves in 48%, white exudates 
in 27%, stenosis in 21% and reduction in caliber 9% [37]. 
None of these endoscopic features is pathognomonic of 
EoE: sensitivity is low, varying between 15% for stenosis 
and 48% for esophagus rings, while the specificity ranged 
between 90% for pale mucosa and 95% for stenosis [37] 
(Fig. 1).
Histology
Esophagus is the only gastrointestinal organ that does 
not present eosinophils in normal condition. The number 
of eosinophil present in mucosa increases progressively 
from stomach to cecum [38]. Even if finding eosinophils 
in esophagus is a pathologic sign, it is not pathognomonic 
of EoE. In fact, other clinical entities, such as gastroe-
sophageal reflux disease (GERD), eosinophilic gastroen-
teritis, parasitosis, celiac disease, Crohn disease, drugs 
hypersensitivity, vasculitis, idiopathic hypereosinophilic 
syndrome, Graft vs Host disease, and scleroderma, can 
present eosinophilic infiltration in esophagus [39].
First of all, it is necessary to perform histology only 
after at least 8 weeks of therapy with PPI to make diag-
nosis of EoE. Then biopsy must present ≥15 eosinophils/
HPF in at least one sample. Other characteristic findings 
are microabscesses, elongation of the papillae, hyperpla-
sia of the basal layer, detachment of the surface layers, 
degranulation of eosinophils, increased number of mast 
cells and lymphocytes [40] (Figs. 2, 3).
Diagnosis
The symptoms mentioned above are not pathogno-
monic of EoE. Also sensibility, specificity and predictive 
value of the endoscopic features are insufficient to make 
a certain diagnosis [41]. Biopsy of esophagus is always 
necessary, even when the macroscopic appearance is 
normal. A study conducted on 66 adults patients con-
firmed that sensibility of histological examination was 
100% when based on the analysis of five samples, while 
it was only 55% if even a single sample was withdrawn 
[42]. These data were validated also in pediatric popula-
tion, in which sensibility was 73, 84, 95 and 100% for 1, 
2, 3 and 6 biopsies, respectively [43]. Thanks to studies 
like these, also guidelines recommend to perform multi-
ple biopsies in proximal, medium and distal esophagus 
[5]. It is also strongly suggested to perform biopsies also 
in stomach and duodenum in order to exclude eosino-
philic gastroenteritis. At least 15 or more eosinophils/
HPF must be found in case of EoE. As mentioned above, 
eosinophils are not present in esophagus in normal con-
dition, but this finding is possible also in other patholo-
gies. In particular two pathologies can present isolated 
eosinophilic esophagitis: GERD and PPI-responsive 
eosinophilic esophagitis. In order to distinguish them 
from EoE, a further biopsy after an 8-week-long therapy 
Fig. 1 EoE
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with PPI must be done. In case of absence of clinical 
and histological response, it is possible to set a diagno-
sis of EoE [40].
It is unclear whether the esophageal eosinophilia 
responsive to PPI is a variant of gastroesophageal 
reflux or a variant of EoE. A small series of four pedi-
atric patients (mean age 9.5  years) with esophageal 
eosinophilia (mean 52 eosinophils/HPF), initially 
responsive to PPI, showed an evolution towards primi-
tive EoE [44]. The reason of the initial response to PPI 
is unclear, though a possible anti-inflammatory activity, 
and for omeprazole also the capacity to block in vitro the 
secretion of eotaxin-3 from esophageal cells, should be 
involved [45].
Fig. 2 Hematoxylin-eosin, 20× magnification: Frustule of esophageal mucosa with diffuse infiltration of eosinophils (Eo > 20/HPF), microabscesses, 
disruption of the epithelial barrier
Fig. 3 Same sample of Fig. 2 in Giemsa, 20× magnification: diffuse eosinophilic infiltration with microabscesses, it can be appreciate also the inter-
cellular edema and the acantholysis resulting from the eosinophils’ degranulation
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Therapy
Treatment of EoE includes pharmacologic, dietetic and 
endoscopic therapy. The appropriate therapy must be 
evaluated according to symptoms and time of response 
with a step-up/step down process. Dietetic and pharma-
cologic treatments are often required for long periods 
as EoE is a chronic disease. No fixed timing is standard-
ized and the duration must be customized to each single 
patient and his/her response.
Pharmacologic therapy
An 8-weeks-long therapy with PPIs is necessary to rule 
out GERD or eosinophilic esophagitis responsive to PPI, 
before an EoE diagnosis can be made.
First line therapy for EoE is represented by topical 
glucosteroids. A great part of patients presents both 
clinical and histological improvement with this treat-
ment [46]. Topical treatment has an anti-inflammatory 
action thanks to ability in inducing some anti-inflam-
matory genes, such as FK-506 binding protein and 
miRs, and in reversing the eosinophilic transcriptome 
[5].
The molecules more frequently prescribed for EoE are 
budesonide and fluticasone. Industry does not provide 
specific formulation for EoE and then available devices 
for asthma must be prescribed to patients. Therefore, 
clinicians must educate subjects to swallow and not to 
inhale corticosteroids in order to have a topic action on 
esophagus.
Doses of fluticasone usually vary between 88 and 
440 mcg/die in children and between 880 and 1760 mcg/
die in adults, while budesonide is 1  mg in children and 
2 mg/die in adults [1]. Only 1% of these swallowed ster-
oids is absorbed and consequently systemic side effects 
are very rare. The most common unwanted effect is oral 
and esophageal candidosis, that can be prevented educat-
ing patients to rinse their mouth after therapy [47].
Occasionally, discrepancy between histological response 
and clinical improvement can be found. In fact, some 
patients continue to present symptoms even if endoscopic 
test is negative. This is probably secondary to the pre-exist-
ing fibrosis and muscle hypertrophy [5]. Pediatric patients 
are indeed more responsive to topical steroids because 
adults have already a significant remodeling of esophagus 
before diagnosis and treatment are performed [48].
Systemic steroids are also very effective to improve 
symptoms, but their use must be limited to the most 
severe cases (i.e. important weight loss secondary to dys-
phagia and/or esophagus stenosis). The recommended 
dose is 1–2 mg/kg (max 60 mg/24 h) for 7–15 days [44]. 
Recurrence of EoE is more frequent after withdrawal of 
systemic steroids [47].
Among the other drugs that were evaluated there are 
biological drugs such as monoclonal antibodies directed 
towards IL-5, IL-13, CRTH2 and IgE, immunomodula-
tors and leukotriene inhibitors. Immunomodulators, 
such as azathioprine and 6-mercaptopurine were used in 
three patients with corticosteroid-dependence obtaining 
long-term remission of EoE, but their use is not currently 
recommended [49]. In contrast, montelukast improves 
clinical symptoms, but is not able to gain histological 
improvement [50].
Omalizumab, an antibody against IgE, failed in gain-
ing both symptoms control and eosinophilic infiltra-
tion in esophageal biopsies [30]. Antibodies against IL-5 
(mepolizumab and reslizumab) were selected to treat 
EoE patients due the fundamental role of this cytokine 
in development and activation of eosinophils, but only a 
limited number of patients have an acceptable response 
to them. Mepolizumab was administered to 11 adults [51] 
and to 45 children [52] in two different trials, obtaining 
decrease of eosinophilic infiltration, but not a significant 
improvement in clinical manifestations. A double-blind 
placebo controlled study on the use of reslizumab was 
performed on 226 children and adolescents, but the dif-
ference in improvements between treated and placebo 
groups was not statistically significant [53]. A recent trial 
studied the effectiveness of QAX576, anti-IL-13 anti-
body, in 23 adult patients, demonstrating a significantly 
decrease of intraepithelial esophageal eosinophilia and 
of the expression of EoE-relevant esophageal transcripts, 
such as eotaxin-3, inducing a sustained clinical improve-
ment [12, 54].
Dietetic therapy
Dietetic therapy of EoE can be effective and it is usually 
prescribed initially together with pharmacologic treat-
ment, even though it is often recommended after drugs 
discontinuation.
Three different treatments have been used during the 
last decades:
1. Elemental diet, during which patients are fed only 
with elemental amino-acid based formula;
2. IgE targeted diet, during which patients must elimi-
nate only food to which they are sensitized.
3. SFED (Six Food Elimination Diet), in which patients 
must exclude the six more probable food allergens: 
milk and dairy products, egg, soy, tree nut/peanut, 
sea food (fish/shellfish);
The first type of diet seems to be very effective to 
induce clinical an histological remission, if given for 
at least 6  weeks [47]. In 1995 Kelly et  al. was the first 
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to demonstrate that a diet based almost exclusively on 
amino acids (only exceptions were corn, apple and clear 
liquids) was successful in obtaining a complete resolu-
tion of clinical manifestations in 8 of 10 children with 
EoE. The remaining two still achieved a significant clini-
cal improvement, and children presented a complete his-
tological remission [55]. Peterson et  al. confirmed these 
data in an adult population of 18 patients: 13 obtained a 
full histological response and 4 presented a reduction of 
50% of the eosinophilia in esophagus [56].
A recent meta-analysis confirmed the efficiency of 
the elemental diet in achieving histologic remission in 
both children and adults in about 90% of the cases [57]. 
The most important limitation of this diet is its strong 
impact on the quality of life. In fact, patients are required 
to drink great amount of liquid, unpalatable and very 
expensive formulas [5, 47].
The second dietetic approach is based on elimina-
tion of foods to which the patient is sensitized. A great 
variability in remission rates has been highlighted in a 
meta-analysis, so that the Authors stated that these data 
are likely to support the involvement of a cell-mediated 
delayed hypersensitivity reaction, instead of an IgE-medi-
ated mechanism underlying EoE pathogenesis [57].
In another study, the foods that clinically caused symp-
toms to patients were compared to sensitizations iden-
tified towards food with skin prick test (SPT). In these 
patients SPT were able to identify the actual trigger food 
only in 13% of cases [58]. Anyway, a target diet with 
elimination of foods inducing positive results to SPT and 
atopy patch test was effective in 26 children with EoE. 
The foods most frequently positive to SPTs are milk, egg, 
peanuts, seafood, peas, rye, tomato and wheat, while the 
most common positivity to atopy patch tests were wheat, 
corn, beef, milk, soy, rye, chicken, oats and potato [58]. 
In adults, the effectiveness of this type of diet is not yet 
clearly demonstrated.
The third dietetic approach is SFED diet. In 2006 
Kagalwalla proposed the empiric use of SFED, starting 
from foods most frequently involved in children allergy 
[59]. The efficacy of SFED was about 70% according to a 
meta-analysis. Such analysis documented that the most 
commonly causative foods involved in relapsing of symp-
toms after their reintroduction were cow’s milk, wheat, 
eggs, and soy/legumes [57].
Endoscopic treatment
In case of severe stenosis (diameter < 10 mm), in patients 
not responsive to pharmacological and/or dietetic ther-
apy, endoscopic dilatation leads to a rapid improvements 
of clinical manifestations. In some cases this remission 
can last several months, but multiple sessions are needed 
to achieve an optimal dilatation. At least an esophageal 
diameter of 15–18 mm must be reached to obtain symp-
toms relief. The risk of perforation after dilatation is low, 
about 0, 1%. Obviously this treatment does not have any 
effect on pathogenetic and inflammatory process [47].
Natural history
Knowledge on long-term prognosis of EoE is actually 
limited. Available data unfortunately indicate a progres-
sive trend towards esophageal fibrosis/stenosis.
A retrospective study in 200 patients highlighted 
that diagnosis’ delay is associated with a higher preva-
lence of fibrostenotic form (from 46.5% for diagnos-
tic delay between 0 and 2  years to 87.5% for diagnostic 
delay >20 years) and is the only factor associated with an 
increased risk of stenosis [60]. These results were also 
confirmed by another recent retrospective analysis: Del-
lon et al. indicated that for every age increase of 10 years 
the risk of having a fibrostenotic form doubled [61]. Sper-
gel et al. followed 620 pediatric patients for over 14 years, 
showing that EoE persisted in the vast majority of cases. 
Fortunately there was not even a case of progression to 
any other gastrointestinal disease [62]. In literature there 
are no reported cases of progression to neoplastic dis-
eases. Actually we can state that, when the diagnosis is 
made during childhood, EoE seems to persist throughout 
adult life, but follow-up studies in the long term are not 
yet available.
Eosinophilic gastroenteritis
Eosinophilic Gastroenteritis (EGE) is a rare and idio-
pathic group of diseases characterized by eosinophilia in 
one or more tracts of gastrointestinal system. If eosino-
philia is limited to stomach, it is defined as eosinophilic 
gastritis; if it is limited to colon, it is called eosinophilic 
colitis. Clinical manifestations are different and never 
specific of this spectrum of disease, also according to the 
interested tract [46].
The precise incidence is unknown, due to EGE rarity, 
but it is rising in the latest years, probably because of a 
better recognition and an increasing interest [63]. Nowa-
days, incidence is estimated about 1–30/100.000, but it is 
probably underestimated [46].
Adults seem to be more affected by EGE then children, 
with a maximum incidence in the fourth–fifth decades. 
Male are slightly more interested than woman (3:2), with 
the exception of serosal subtype. Even in this case, EGE is 
more common in Caucasians [46, 64].
About 70% of patients suffering from EGE present a 
personal or familiar history of atopy. The most common 
allergies presented by these patients are food sensitiza-
tions [65].
Page 8 of 11Ridolo et al. Clin Mol Allergy  (2016) 14:17 
Pathogenesis
EGE etiology and pathogenesis are not clearly defined. 
Delayed type hypersensitivity to food is the most proba-
ble underlying mechanism, according to the current data. 
In these patients hypereosinophilia found in peripheral 
blood and in gastrointestinal tissue, increased serum lev-
els of IgE, presence of elevated mediators produced by 
eosinophils in intestinal biopsies and response to steroids 
therapy are supporting this pathogenetic hypothesis [46].
Classification and clinical manifestations
Anatomic localization of eosinophilic inflammation 
influences clinical manifestations, that can vary from 
nausea to intestinal obstruction. As a consequence, EGE 
is classified according to the most infiltrated layer of the 
intestinal wall in [66]:
1. Mucosal the most common subtype. Patients have 
non-specific symptoms, such as nausea, vomiting, 
diarrhea, anemia due to chronic inflammation or 
iron deficiency, clinical manifestations secondary to 
malabsorption. In particular, in children weight loss 
and protein losing enteropathy are the most common 
manifestations [40, 63].
2. Muscular the second form for frequency. The inter-
est of this layer often leads to intestinal obstruction 
secondary to the thickening of intestinal wall [67]. 
The most common is jejunal obstruction [38]. Colo-
colonic intussusceptions are rare [68].
3. Serosal the most uncommon subtype, even though is 
the most frequent in females [40]. Clinical presenta-
tion begins usually with ascites, sometimes associ-
ated with symptoms of intestinal obstruction. Ascites 
is characterized by marked eosinophilia in ascitic 
fluid. Serosal subtype differs also for its consistent 
response to corticosteroids therapy [40, 63].
EGE subtypes, correlate with prognosis. Serosal pattern 
in fact does not present a continuous chronic course, but 
mostly single episodic flares up, with long disease-free 
periods. Instead, mucosal subtype is characterized by a 
persistent presence of symptoms and muscular pattern 
presents frequent relapses [69].
It must be noted anyway that it is difficult in everyday 
practice to distinguish which is the most involved layer 
for two reasons: overlap among 2 or 3 subtypes is very 
common and often only mucosal and submucosal biop-
sies are taken [69].
Endoscopic and histological aspects
Often, endoscopic aspects, either for stomach and 
for colon, can be normal or demonstrate non-specific 
aspects of chronic inflammation [70]. Mucosal erythema, 
friability, ulcerated mucosa, mucosal nodules or whitish 
specks can be also found [63] (Figs. 4, 5).
Diagnosis must be based on the finding of eosinophilic 
infiltration of mucosa. There is not a universally accepted 
threshold of eosinophils/HPF, in fact they are present in 
normal conditions in gastroenteric tract (only exclusion 
is esophagus). The most accepted definition is a count 
that exceeds 20  Eo/HPF [63, 70] in at least one sample. 
Besides eosinophils, a higher concentration of theirs 
mediator can be found in biopsies, in particularly met-
alloproteinases and eosinophilic cationic protease, IL-3, 
IL-5 and GMCSF [40, 63].
Since distribution of eosinophilic infiltration is not 
linear and can be present even in areas macroscopically 
normal, multiple biopsies are necessary [63].
Diagnosis
Establishing a diagnosis of EGE is not easy: in fact, sin-
gle laboratory tests or procedures that allow to identify 
this disease are lacking. Certainly, patients must present 
chronic or recurrent gastrointestinal symptoms, with 
documented eosinophilic infiltration of one or more gas-
trointestinal areas. Then, other causes of gastrointestinal 
eosinophilia and eosinophilic infiltration in other organs 
must be excluded.
If EGE is suspected, a blood sample must be collected. 
In fact, up to 80% of these patients presents peripheral 
eosinophilia. It appears to be more severe in patients 
affected by serosal subtype of EGE [71]. Anyway, it does 
not correlate with the activity of disease and it must not 
be used for follow up during or after therapy [72].
Moreover, before setting the diagnosis, it must be 
included [63]:
  • Endoscopic and histological evaluations, that must 
present the characteristic mentioned above.
  • Exclusion of other causes of gastrointestinal eosino-
philia, such as hypereosinophilic syndrome, eosino-
philic granulomatosis with polyangiitis (EGPA), 
celiac disease, inflammatory bowel disease, polyarte-
ritis nodosa, other connective tissue disorders, infec-
tions, and drug hypersensitivity, through the use of 
careful collected history, laboratory testing and histo-
logical examination.
Once diagnosis of EGE is established, allergy evaluation 
must be carried out. In fact, up to 70% of patients with 
EGE can present a personal or family history of atopy, 
especially food allergy is very common [73]. Food aller-
gies may be a trigger of clinical manifestations and/or 
pathogenesis of EGE. Atopy’s role is not yet well defined, 
also because EGE seems to be determined by both an IgE 
mediated mechanism and IgE-mediated- Th2 delayed 
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hypersensitivity process. Anyway, allergen-specific 
in  vitro or in  vivo tests are indicated in these patients, 
because, if positive, elimination of causative foods is 
effective on symptoms [74].
Therapy
Treatment of EGE includes dietetic and pharmacological 
approach. Surgery or other kind of therapy (i.e. paracen-
tesis) may be needed in case of complications.
Dietetic therapy
Following the benefits obtained in patients with EoE, a 
dietetic approach was tested also in EGE subjects. Nowa-
days, data about efficacy of dietetic treatment are based 
on case reports or on small series of patients. Chehade 
demonstrated the effectiveness of elemental diet in six 
pediatric patients [75], while SFED diet was tested in one 
child with benefit [76]. Data available about IgE-targeted 
diet are discordant [63].
Pharmacological therapy
Corticosteroids therapy represents the main therapy for 
EGE and is effective in about 80% of patients [38]. There 
are not randomized trials for EGE therapy. In literature 
the most common first approach is systemic corticos-
teroid therapy with 20–40  mg/daily of prednisone for 
2–6 weeks. In some cases this treatment was then contin-
ued with topic budesonide with benefit [77–79].
Other therapeutic approaches (mast cell stabilizers, 
omalizumab, mepolizumab, reslizumab, infliximab, leu-
kotriene inhibitors, antihistaminic drugs, Th-2 inhibitors, 
such as suplatast and CRTH2) have been investigated, 
but their efficacy is not yet well defined, even because of 
the small number of patients involved.
Abbreviations
BANCR: BRAF-activated non-coding RNA; CAPN14: calpain 14; DSG1: desmo-
glein 1; EoE: eosinophilic esophagitis; EGE: eosinophilic gastroenteritis; EGIDs: 
eosinophilic gastrointestinal diseases; EGPA: eosinophilic granulomatosis with 
polyangiitis; GERD: gastroesophageal reflux disease; GM-CSF: granulocyte-
macrophage colony-stimulating factor; HPF: high power field; iNKT: invariant 
natural killer T; NGF: neurotropic tyrosine kinase; NTRK1: neurotropic tyrosine 
kinase receptor type 1; PPI: proton pump inhibitor; SFED: six food elimination 
diet; SNP: single nucleotide polymorphism; SPT: skin prick test; TGF- β: trans-
forming growth factor-beta; TNF-α: tumor necrosis factor alpha; TSLP: thymic 
stromal lymphopoietin.
Authors’ contributions
ER conceived the study, contributed to the writing and coordinated the draft 
of the manuscript. IM, VM, contributed to the draft of the manuscript and to 




The authors declare that they have no competing interests.
Received: 13 September 2016   Accepted: 10 November 2016
Fig. 4 Eosinophilic gastroduodenitis, bulb mucosa
Fig. 5 Eosinophilic colitis
Page 10 of 11Ridolo et al. Clin Mol Allergy  (2016) 14:17 
References
 1. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated 
consensus recommendations for children and adults. J Allergy Clin 
Immunol. 2011;128:3–20.
 2. Hruz P. Epidemiology of eosinophilic esophagitis. Dig Dis. 2014;32:40–7.
 3. van Rhijn BD, Verheij J, et al. Rapidly increasing incidence of eosinophilic 
esophagitis in a large court. Neurogastroenterol Motil. 2013;25:47–52.
 4. Spergel JM. New genetic links in eosinophilic esophagitis. Genome Med. 
2010;2:60.
 5. Guarino MPL, Cicala M, Behar J. Eosinophilic esophagitis: new insight 
in pathogenesis and therapy. World J Gastroinest Pharmacol Ther. 
2016;7(1):66–77.
 6. Alexander ES, Martin LJ, Collins MH, et al. Twin and family studies reveal 
strong environmental and weaker genetic cues explaining heritability of 
eosinophilic esophagitis. J Allergy Clin Immunol. 2014;134(5):1084–92.
 7. Abonia JP, Wen T, Stucke EM, et al. High prevalence of eosinophilic 
esophagitis in patients with inherited connective tissue disorders. J 
Allergy Clin Immunol. 2013;132(2):378–86.
 8. Davis BP, Epstein T, Kottyan L, et al. Association of eosinophilic 
esophagitis and hypertrophic cardiomyopathy. J Allergy Clin Immunol. 
2016;137(3):934–6.
 9. Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and uniquely conserved 
gene-expression profile in eosinophilic esophagitis. J Clin Invest. 
2006;116:536–47.
 10. Sherill JD, Gao P, Stucke EM, et al. Variation of thymic stromal lymphopoi-
etin and its receptor associate with eosinophilic esophagitis. J Allergy Clin 
Immunol. 2010;126:160–5.
 11. Blanchard C, Stucke EM, Burwinkel K, et al. Co-ordinate interaction 
between Il-13 and epithelial differentiation cluster genes in eosinophilic 
esophagitis. J Immunol. 2010;184:4033–41.
 12. Blanchard C. Molecular pathogenesis of eosinophilic esophagitis. Curr 
Opin Gastroenterol. 2015;31:321–7.
 13. Chandramouleeswaran PM, Shen D, Lee AJ, et al. Preferential secretion 
of thymic stromal lymphopoietin (TSLP) by terminally differentiated 
esophageal epithelial cells: relevance to eosinophilic esophagitis (EoE). 
PLoS ONE. 2016;11(3):e0150968.
 14. Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithe-
lial barrier function and immune responses in eosinophilic esophagitis. 
Mucosal Immunol. 2014;7:718–29.
 15. Singla MB, Moawad FJ. An overview of the diagnosis and management of 
eosinophilic esophagitis. Clin Transl Gastroenterol. 2016;7:e155.
 16. Gupta SK, Fitzgeraald JF, Kondratyuk T, HogenEsh H. Cytokine expression 
in normal and inflamed esophageal mucosa: a study into the patho-
genesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 
2006;42:22–6.
 17. Blanchard C, Mingler MK, Vicario M, et al. IL-13 involvement in eosino-
philic esophagitis: transcriptome analysis and reversibility with glucocor-
ticoids. J Allergy Clin Immunol. 2007;120:1292–300.
 18. Davis BP, Stucke EM, Khorki ME, et al. Eosinophilic esophagitis-linked cal-
pain 14 is an IL-13-induced protease that mediates esophageal epithelial 
barrier impairment. JCI Insight. 2016;1(4):e86355.
 19. Sherill JD, Kiran KC, Blanchard C, et al. Analysis and expansion of the 
eosinophilic esophagitis transcriptome by RNA sequencing. Genes 
Immun. 2014;15:361–9.
 20. Rochman M, Kartashov AV, Caldwell JM, et al. Neurotrophic tyrosine 
kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 
involved in allergic inflammation. Mucosal Immunol. 2015;8(4):785–98.
 21. Zhang S, Wu X, Yu S. Prostaglandin D2 receptor D-type prostanoid recep-
tor 2 mediates eosinophil trafficking into the esophagus. Dis Esophagus. 
2014;27(6):601–6.
 22. Niranjan R, Mavi P, Rayapudi M, Dynda S, Mishra A. Pathogenic role of 
mast cells in experimental eosinophilic esophagitis. Am J Physiol Gastro-
intest Liver Physiol. 2013;304(12):G1087–94.
 23. Rayapudi M, Rajavelu P, Zhu X, et al. Invariant natural killer T-cell neutrali-
zation is a possible novel therapy for human eosinophilic esophagitis. 
Clin Transl Immunol. 2014;3:e9.
 24. Jyonouchi S, Smith CL, Saretta F, et al. Invariant natural killer T cells in 
children with eosinophilic esophagitis. Clin Exp Allergy. 2014;44:58–68.
 25. Roy-Ghanta S, Larosa DF, Katzka DA. Atopic characteristics of adult 
patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 
2008;6:531–5.
 26. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J 
Med. 2004;351:940–1.
 27. Ridolo E, De Angelis GL, Dall’aglio P. Eosinophilic esophagitis after specific 
oral tolerance induction for egg protein. Ann Allergy Asthma Immunol. 
2011;106:73–4.
 28. Sánchez-García S, Rodríguez Del Río P, Escudero C, et al. Possible eosino-
philic esophagitis induced by milk oral immunotherapy. J Allergy Clin 
Immunol. 2012;129(4):1155–7.
 29. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis 
and oral immunotherapy for food allergy: a systematic review with meta-
analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–9.
 30. Clayton F, Fang JC, Gleich GJ, et al. Eosinophilic esophagitis in adults 
is associated with IgG4 and not mediated by IgE. Gastroenterology. 
2014;147:602–9.
 31. Yamazaki K, Murray JA, Arora AS, et al. Allergen-specific in vitro cytokine 
production in adult patients with eosinophilic esophagitis. Dig Dis Sci. 
2006;51:1934–41.
 32. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. An etiological role for 
aeroallergens and eosinophils in experimental esophagitis. J Clin Invest. 
2001;107:83–90.
 33. Ridolo E, Montagni M, Olivieri E, et al. Eosinophilic esophagitis: which role 
for food and inhalant allergens? Asia Pac Allergy. 2012;2:237–41.
 34. Van Rhijn BD, van Ree R, Versteeg SA, et al. Birch pollen sensitization with 
cross-reactivity to food allergens predominates in adults with eosino-
philic esophagitis. Allergy. 2013;68:1475–81.
 35. Ridolo E, Montagni M, Melli V, et al. A role for pathogenesis-related 
proteins in poy-sensitized allergic patients with eosinophilic esophagitis: 
clinical and endoscopic features. J Allergy Ther. 2014;5:6.
 36. Miehlke S. Clinical features of eosinophilic esophagitis. Dig Dis. 
2014;32:61–7.
 37. Joo MK, Park JJ, Kim SH. Prevalence and endoscopic features of eosino-
philic esophagitis in patients with esophageal or upper gastrointestinal 
symptoms. J Dig Dis. 2012;13(6):296–303.
 38. DeBrosse CW, Case JW, Putnam PE, et al. Quantity and distribution of 
eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol. 
2006;9:201–8.
 39. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced 
based approach to the diagnosis and management of esophageal 
eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 
2013;108(5):679–92.
 40. Alhmoud T, Hanson JA, Parasher G. Eosinophilic gastroenteritis: an under-
diagnosed condition. Dig Dis Sci. 2016. [Epub ahead of print].
 41. Kim HP, Vance RB, Shaheen NJ, Dellon ES. The prevalence and diagnostic 
utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. 
Clin Gastroenterol Hepatol. 2012;10(9):988–96.
 42. Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic vari-
ability and endoscopic correlates in adults with eosinophilic esophagitis. 
Gastrointest Endosc. 2006;64(3):313–9.
 43. Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variabil-
ity in children with eosinophilic esophagitis. Am J Gastroenterol. 
2009;104(3):716–21.
 44. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal 
eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic 
esophagitis. Dig Dis Sci. 2012;57(5):1413–9.
 45. Park JY, Zhang X, Nguyen N, et al. Proton pump inhibitors decrease 
eotaxin-3 expression in the proximal esophagus of children with esopha-
geal eosinophilia. PLoS ONE. 2014;9(7):e101391.
 46. Cianferoni A, Spergel JM. Eosinophilic esophagitis and gastroenteritis. 
Curr Allergy Asthma Rep. 2015;15:58.
 47. Ahmed M. Eosinophilic esophagitis in adults. World J Gastrointest Phar-
macol Ther. 2016;7(2):207–13.
 48. Lucendo AJ, Arias A, De Rezende LC, et al. Subepithelial collagen deposi-
tion, profibrogenic cytokine gene expression, and changes after pro-
longed fluticasone propionate treatment in adult eosinophilic esophagi-
tis: a prospective study. J Allergy Clin Immunol. 2011;128:1037–46.
 49. Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-dependent 
eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can 
induce and maintain long-term remission. Eur J Gastroenterol Hepatol. 
2007;19(10):865–9.
 50. Attwood SE, Lewis CJ, Bronder CS, et al. Eosinophilic esophagitis: a novel 
treatment using Montelukast. Gut. 2003;52:181–5.
Page 11 of 11Ridolo et al. Clin Mol Allergy  (2016) 14:17 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 51. Beglinger C, Smith DA, Patel J, et al. Antiinterleukin-5 antibody treat-
ment (mepolizumab) in active eosinophilic oesophagitis: a randomised, 
placebo-controlled, double-blind trial. Gut. 2010;59:21–30.
 52. Dohil R, Broide DH, Aceves SS. Anti-IL-5 therapy reduces mast cell and IL-9 
cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy 
Clin Immunol. 2013;131:1576–82.
 53. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children 
and adolescents with eosinophilic esophagitis: results of a double-
blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 
2012;129:456–63.
 54. Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb 
QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin 
Immunol. 2015;135:500–7.
 55. Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed 
to gastroesophageal reflux: improvement with an amino acid-based 
formula. Gastroenterology. 1995;109(5):1503–12.
 56. Peterson KA, Byrne KR, Vinson LA, et al. Elemental diet induces histo-
logic response in adult eosinophilic esophagitis. Am J Gastroenterol. 
2013;108(5):759–66.
 57. Arias A, González-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary 
interventions for inducing histologic remission in patients with eosino-
philic esophagitis: a systematic review and meta-analysis. Gastroenterol-
ogy. 2014;146(7):1639–48.
 58. Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats 
eosinophilic esophagitis in adults; food reintroduction identifies causa-
tive factors. Gastroenterology. 2012;142(7):1451–9.
 59. Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination 
diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin 
Gastroenterol Hepatol. 2006;4(9):1097–102.
 60. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of 
eosinophilic esophagitis increases risk for stricture formation in a time-
dependent manner. Gastroenterology. 2013;145(6):1230–6.
 61. Dellon ES, Kim HP, Sperry SL, et al. A phenotypic analysis shows that 
eosinophilic esophagitis is a progressive fibrostenotic disease. Gastroin-
test Endosc. 2014;79(4):577–85.
 62. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosino-
philic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol 
Nutr. 2009;48(1):30–6.
 63. Uppal V, Kreiger P, Kutsch E. Eosinophilic gastroenteritis: a comprehensive 
review. Clin Rev Allergy Immunol. 2016;50:175–88.
 64. Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment out-
comes, and resource utilization in children and adults with eosinophilic 
gastroenteritis. Dig Liver Dis. 2015;47(3):197–201.
 65. Khan S, Orenstein SR. Eosinophilic gastroenteritis: epidemiology, diagno-
sis and management. Paediatr Drugs. 2002;4(9):563–70.
 66. Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroen-
teritis. Medicine. 1970;49:299–319.
 67. Yun MY, Cho YU, Park IS, et al. Eosinophilic gastroenteritis presenting as 
small bowel obstruction: a case report and review of the literature. World 
J Gastroenterol. 2007;13:1758–60.
 68. Box JC, Tucker J, Watne AL, Lucas G. Eosinophilic colitis presenting as a left-
sided colocolonic intussusception with secondary large bowel obstruction: 
an uncommon entity with a rare presentation. Am Surg. 1997;63:741–3.
 69. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of 
eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9:950–6.
 70. Chen MJ, Chu CH, Lin SC, et al. Eosinophilic gastroenteritis: clinical experi-
ence with 15 patients. World J Gastroenterol. 2003;9:2813–6.
 71. von Wattenwyl F, Zimmermann A, Netzer P. Synchronous first manifesta-
tion of an idiopathic eosinophilic gastroenteritis and bronchial asthma. 
Eur J Gastroenterol Hepatol. 2001;13:721–5.
 72. Ko HM, Morotti RA, Yershov O, et al. Eosinophilic gastritis in children: 
clinicopathological correlation, disease course, and response to therapy. 
Am J Gastroenterol. 2014;109:1277–85.
 73. Maloney J, Nowak-Wegrzyn A. Educational clinical case series for pediat-
ric allergy and immunology: allergic proctocolitis, food protein-induced 
enterocolitis syndrome and allergic eosinophilic gastroenteritis with 
protein-losing gastroenteropathy as manifestations of non-IgE-mediated 
cow’s milk allergy. Pediatr Allergy Immunol. 2007;18:360–7.
 74. Ishimura N, Furuta K, Sato S, et al. Limited role of allergy testing in 
patients with eosinophilic gastrointestinal disorders. J Gastroenterol 
Hepatol. 2013;28:1306–13.
 75. Chehade M, Sicherer SH, Magid MS, et al. Multiple exudative ulcers and 
pseudopolyps in allergic eosinophilic gastroenteritis that responded to 
dietary therapy. J Pediatr Gastroenterol Nutr. 2007;45:354–7.
 76. Yamada Y, Kato M, Isoda Y, et al. Eosinophilic gastroenteritis treated with a 
multiple-food elimination diet. Allergol Int. 2014;63(Suppl 1):53–6.
 77. Iborra M, Alvarez-Sotomayor D, Nos P. Long-term safety and efficacy of 
budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol. 
2014;7:39–46.
 78. Siewert E, Lammert F, Koppitz P, et al. Eosinophilic gastroenteritis with 
severe protein-losing enteropathy: successful treatment with budeson-
ide. Dig Liver Dis. 2006;38:55–9.
 79. Tan AC, Kruimel JW, Naber TH. Eosinophilic gastroenteritis treated with 
non-enteric-coated budesonide tablets. Eur J Gastroenterol Hepatol. 
2011;13:425–7.
